Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137537 | 1.00 | GAA (0.46) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL4136135 | 0.87 | KMT2A (0.57) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL4136132 | 0.87 | KMT2A (0.57) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL4137544 | 0.86 | HSD11B1 (0.54) | GAAALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL4136991 | 0.85 | GAA (0.48) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL4136993 | 0.85 | GAA (0.48) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL4130977 | 0.85 | KMT2A (0.46) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL4130980 | 0.85 | KMT2A (0.46) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL4141017 | 0.84 | GAA (0.48) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL4141021 | 0.84 | GAA (0.48) | GAAALDH1A1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156644-A1 | Use of thiazole derivatives and analogues in the treatment of cancer | BETAGENON AB (SE) | 2009-06-18 | — | — | US | disclosed |
| US-20090136472-A1 | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | BETAGENON AB (SE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008065409-A2 | COMBINATION FOR USE IN THE TREATMENT OF CANCER, COMPRISING TAMOXIFEN OR AN AROMATASE INHIBITOR | BETAGENON AB (SE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156644-A1 | Use of thiazole derivatives and analogues in the treatment of cancer | TBXA2R, TSHR, FOLR1 | GAA 2671/4885ALDH1A1 312/4885LMNA 2911/4885 |
| US-20090136472-A1 | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | FFAR2, FFAR1, FFAR4 | GAA 1211/4885ALDH1A1 707/4885LMNA 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.